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1. Introduction
  With more than 3% of the world’s population infected 
by hepatitis C virus (HCV), this disease has become a 
major public health challenge[1]. HCV infection is a severe 
health problem, causing approximately 20% of acute 
hepatitis, 80% of chronic hepatitis, 40% of hepatocirrhosis, 
70% of hepatocellular carcinoma, and 30% of liver 
transplantations[2]. HCV infection is endemic in Iran and 
the prevalence rate varied from 0.08% to 1.3% in the central 
and northern of Iran, respectively[3]. Some groups of patients 
in different exposure categories such as individuals with 
haemophilia, thalassemia, end patients with stage renal 
disease under hemodialysis (HD), and intravenous drug 
addicts  (IDAs) are at high risk of acquiring HCV infection. 
  HCV is a small, enveloped, single-stranded, positive 
sense RNA virus with a large genetic heterogeneity rate. 
Based on a nucleotide sequence divergence, isolates have 
been classified into 6 major genotypes and more than 70 
subtype[4]. These genotypes differ by 31% to 34% in their 
nucleotide sequence and by around 30% in their amino 
acid sequence. The prevalence of HCV genotypes differs 
substantially in distinct geographical regions. On the other 
hand, HCV genotypes 1, 2, and 3 distribute all over the world 
with some variation in their prevalence from one geographic 
region to others[5]. HCV genotyping is mainly useful for the 
clinical management of infected patients and for facilitating 
decisions on therapy, as genotypes 1 and 4 are less likely 
than genotypes 2 and 3 to respond to interferon[6]. 
  HCV is principally acquired and transmitted by parenteral 
route including blood transfusion, intravenous drug abuse 
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and nosocomial transmission. The high-risk groups of 
HCV infection include hemophiliacs, intravenous drugs 
addicts, and patients with end-stage renal disease under 
hemodialysis[7]. There is no vaccine against HCV and 
available treatments are long, difficult, and expensive and 
will not work for all the patients. In Iran, HCV infection, 
mostly occurred due to problems like increasing population 
of drug addicts and common needle-sharing among , 
using blood or it’s infected derivatives in surgery or to 
survival of thalassemia, haemophilia and patients under 
hemodialysis[7,8]. Although frequent blood transfusion led to 
continue survival of these specific patient groups, but due 
to non-compliance with important health tips on infection 
control in dialysis units and other health care centers, these 
patients are at high risk of affecting blood borne pathogens, 
particularly HCV[9,10]. Precise data of HCV genotypes pattern 
and continuous monitoring of the genetic diversity of HCV 
isolates, especially among high-risk individuals in our 
community, is essential for understanding of epidemiology, 
pathogenesis, and successful management of the patients. 
  Since there is inadequate data about genotype pattern of 
HCV infection among high risk groups from different regions 
of Iran especially for north of Iran, we carried out this study 
to provide molecular epidemiology data of HCV genotype 
pattern among high-risk individuals. 
2. Materials and methods
2.1. Study population
   A cross-sectional study was carried in Mazandaran 
province, north of Iran, during July 2009 to September 
2011. Individuals with HCV infection who were recruited 
by the Blood Bank of Sari, Department of Infectious 
Diseases, Razi Hospital, Thalassemia and Hemophilia 
Associations, and Center for Prevention and Treatment 
of Chemical Dependency. A questionnaire was used 
in face to face interview to collect some demographic 
information, epidemiological features such as; age, sex, 
history of intravenous drug addiction, tattooing, treatment 
with interferon, duration of HCV infection, and history 
of hospitalization. All thalassemia patients were beta 
thalassemia major and received regular blood transfusions 
at 4 week intervals to maintain haemoglobin level at 10-
13 g/dL along with regular therapy with deferoxamine. All 
hemophilia patients were hemophilia A and they have 
mainly injected whole blood cells or blood derivatives 
such as clotting factor concentrates, cryoprecipitate and 
fresh frozen plasma. Most of the IDAs population studied 
was multiple drug users with high levels of consumption of 
heroine (37.2%), crack (44.2%), cocaine (6.7%), opium paste 
(51.6%). The duration of drug use varied from 2 to 10 years. 
The protocol used in the present study was approved by 
the Ethical Committee of Mazandaran University of Medical 
Sciences and written informed consent was obtained from 
each patient.  
2.2. Serological test
  Plasma samples were obtained from four high risk 
patient groups chronically infected with HCV, thalassemia, 
hemophilia, end stage renal disease under HD, IDAs, all 
of whom were seronegative for hepatitis B virus, human 
immunodeficiency virus, and autoimmune markers. 
The presence of anti-HCV antibody was tested by a 
third-generation enzyme immunoassay (Ortho-Clinical 
Diagnostics, Raritan, NJ, USA) detecting reactivity to 
three HCV recombinant proteins (c22-3, c200 and NS5) 
originating from four regions of viral genomes: core, NS3, 
NS4 and NS5. All samples reactive on ORTHO HCV Version 
3.0 ELISA Test System were tested with the confirmatory 
recombinant immunoblotting assay, RIBA (Chiron RIBA HCV 
3.0 SIA; Chiron Corp., Emeryville, CA, USA) according to the 
manufacturers’ instructions. 
 
2.3. HCV-RNA detection and genotyping
 All HCV positive plasma samples were submitted to RNA 
extraction by using QIAamp襅Viral RNA Kit (QIAGEN, 
Valencia, CA, USA), according to the manufacturer’s 
instructions. For complementary DNA (cDNA) synthesis, 
a transcriptase reaction was performed using MMLV-
reverse transcriptase, random hexamer, dNTP, and RANase 
inhibitor in the final volume reaction 50 毺L according to 
the following thermal profile: 70 曟 for 10 minutes, 25 曟 for 
15 minutes, 37 曟 for 60 minutes and 95 曟 for 15 minutes 
in a thermocycler (Eppendorf Mastercycler, Eppendorf, 
Hamburg, Germany). HCV genotypes were determined on 
all HCV-RNA positive samples by using AmpliSens襅HCV- 
genotype kit ((Russia, Moscow) according to manufacturer’s 
instructions. The Kit can specify genotype and subtypes 1a, 
1b, 2, 3a, and 4 with different product sizes 388, 395, 412, 286 
and 227 base pairs. The hot-start protocol was applied to 
decrease the level of non-specific priming. Thermal profile 
of PCR program was as follow: initial denaturation in 95 曟 
for 5 min follow by 35 cycles of 94 曟 for 1 min, 68.5 曟 for 
1 min, 72 曟 for 1 min, and final extension in 72 曟 for 1 
min. PCR products were electrophoresed on 2.5% agarose 
gel and visualized by staining with ethidium bromide 
under ultraviolet light. To avoid cross-contamination 
between samples, standard precautions were used in all 
manipulations. Separate areas were used when handling 
reagents and samples and manipulating amplified products.
2.4. Statistical analysis
  Clinical and demographic continuous data were 
summarized as mean暲SD, and categorical data were 
summarized by absolute frequencies or percentages. 
Comparisons of continuous or categorical variables were 
preformed with ANOVA or chi square tests. All P values 
were evaluated in a two-sided model, and P敿0.05  was 
considered statistically significant. All analysis performed 
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using SPSS Version 17 (SPSS, Inc., Chicago, IL).  
3. Results
3.1. Demographic and risk factors among study population
  Among the 187 positive anti-HCV samples, only 135 (72.2%) 
gave HCV-specific positive signals by PCR of the 5’-UTR 
of HCV. The group of 135 Iranian was composed mainly of 
males 94 (69.6%). The mean age was (35.1暲12.0) years. Of 
the participants, 34 (25.18%) thalassemia, 31 (22.96%) HD, 
33 (24.45%) hemophilia and 37 (27.41%) IDAs were found 
to be positive for anti-HCV and HCV-RNA. The baseline 
characteristics of the study population were shown in Table 
1. The distribution of age and gender in the study subgroups 
were statistically significant differences. On the other hand, 
thalassemic individuals and HD patients had the minimum 
and maximum mean age, respectively (P<0.0001). Meanwhile, 
hemophilia and IDAs were prominently males (P<0.0001). 
In addition, the duration of HCV infection was more in HD 
patients than that other HCV high risk groups (P<0.0001). 
Seventy six (56.9%) out of 135 individuals had hospitalization 
history and thalassemia had more times hospitalization than 
the other groups. Forty eight percent of patients reported a 
history of surgery for at lease one time. A total of 20 (58.8%) 
out of 34 thalassemia patients were splenectomized.  Twenty 
four out of 135 patients had a history of tattoo, among them; 
IDAs were prominent (64.9%). Fifty two (38.5%) HCV-RNA 
individuals underwent pegylated interferon alpha therapy. 
Thalassemia and hemophilia received this treatment more 
than the other groups. The mean levels of liver enzymes 
such as AST and ALT were found to be approximately more 
than 1.5 times higher than their normal levels and were 
found to be statistically significant between HCV-RNA 
infected thalassemia, IDAs, and HD patients. On the other 
hand, the mean levels of ALT in thalassemia and hemophilia 
was found to be two times higher than their normal levels 
(<40 IU/L). 
3.2. HCV-RNA prevalence and HCV genotypes
   Genotype analysis was performed on the HCV RNA-
positive samples and Table 2 summarizes HCV genotypes 
in our participants. Over all, the most identified HCV type 
was genotype 3a (51.1%) followed by 1a (27.4%), 1b (8.2%). 
On the other hand, 16 (11.86%) out of 135 HCV RNA-positive 
participants were infected with more than one genotype or 
subtypes as follow; 1a/1b in 11 (8.2%), 2/3a in 3 (2.2%), and 
1a/1b/3a in 2 (1.5%). In addition, we could not type 2 (1.5%) 
of our patients by using Amplisens HCV genotyping kit. 
Stratification of our participants to four high risk groups 
revealed that HCV subtype 3a was more prominent in the 
high risk groups except IDAs. So that the prevalence of 
subtype 3a were 24 (77.42%), 15 (44.12%), and 25 (75.76%) in 
HD, thalassemia, and hemophilic patients, respectively.  The 
prevalence of type 1 in IDA subjects was higher than that 
type 3a (56.76 vs. 13.51, respectively). Interestingly, among 
all study groups, subtype 1b and mixed subtypes 1a/1b 
were only prominent in IDAs participants (27.03%, 29.73%, 
respectively). Mixed types of 2/3a were only found in 3 (8.82) 
thalassemic patients. Analysis of HCV genotype frequency 
across thalassemic patients with positive history of surgery 
revealed that only subtype 1a found in splenoctomized 
patients.
Table 1 
Basic characteristics of different HCV RNA positive high risk patients.
Group Total (n=135) Thalassemia(n =34) Hemophilia(n =33) HD(n =31) IDAs(n =37) P-value
Age 35.1暲12.0 26.6暲4.9 32.4暲8.7  47.4暲13.1 34.9暲9.7 <0.0001
Sex (male/female) 94/41 17/17 31/2 13/18 33/4 <0.0001
Duration of infection (month) 60.8暲57.7 71.8暲42.4 62.1暲46.7 90.6暲40.7 22.0暲11.4 <0.0001
Hospitalization 76 (56.9) 27 (79.4) 8 (24.2) 19 (51.4) 22 (59.5) <.0.0001
History of surgery 48 (35.6) 20 (58.8) 5 (15.15) 4 (12.9) 19 (51.4) <0.0001
Tattoo 24 (17.8) - 1 (3.0) - 23 (64.9) <0.0001
Interferon therapy 52 (38.5) 19 (55.9) 15 (45.5) 10 (32.3) 8 (21.6) <0.0001
AST (IU/L) 64.5暲24.7 75.6暲32.3 61.2暲30.8 30.92暲15.3 69.8暲44.3 0.015
ALT (IU/L) 70.5暲43.8 81.9暲42.9  58.8暲25.2 28.45暲17.7 80.1暲45.2 0.003
Normal levels: AST, <40IU/L; ALT, <40 IU/L.
Table 2
Distribution of HCV genotypes among different high rick group of patients. 
Genotype Total[n (%)] HD(n =31) Thalassemia(n =34) Hemophilia(n =33) IDAs(n =37)
1a 37(27.40)   6(19.36) 13(38.24)   7(21.21) 11(29.73)
1b 11(8.20)   0(0.00)   1(2.94)   0(0.00) 10(27.03)
3a 69(51.10) 24(77.42) 15(44.12) 25(75.76)   5(13.51)
Mixed genotype 1a, 1b 11(8.20)   0(0.00)   0(0.00)   0(0.00) 11(29.73)
2, 3a   3(2.20)   0(0.00)   3(8.82)   0(0.00)   0(0.00)
1a, 1b, 3a   2(1.50)   1(3.22)   1(2.94)   0(0.00)   0(0.00)
Non typable    2(1.50)   0(0.00)   1(2.94)   1(3.03)   0(0.00)
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4. Discussion
   The main finding of this study was the dominancy of 
genotypes 3a and 1a among groups of patients in different 
exposure categories. On the other hand, the frequency of 
genotypes 3a and 1 were 51.1% and 35.6% in over all. The 
distribution of HCV genotypes in our multiply injected 
subjects is similar to those that previously reported from 
Iran[11-14] which shown prominence of genotype 3a and 
1a while 1b and 2 are less frequent and other genotypes 
(4 and 5) are rare in HCV-RNA positive individuals[13,15]. 
Meanwhile, other studies have reported more frequency 
of genotype 1a and 3a in thalassemia[16,17]. HCV genotypes 
distribution in our subjects with different exposure 
categories is similar to the reported pattern on some HCV 
high risk population in northern Europe, where genotypes 
1, 2 and 3 are more frequent[18,19].  In Iran, variations of HCV 
infection prevalence have been reported, depending upon 
the geographical region. In a population-based study from 
different parts of Iran, Amini et al reported that 1a, 3a, and 
1b were the predominant genotypes[11]. On the other hand, 
since the main subjects of our study population originated 
from Mazandaran, north of Iran, a prominence 3a genotype 
which detected in our subjects was in line with other studies 
shown subtype 3a was more frequent in north of Iran whereas 
subtype 1a was dominant in south of Iran[13,14,16,20,21]. 
Distribution of HCV genotypes vary in our neighboring 
countries. So that genotype 3a was frequently reported form 
Pakistan[22,23], India[24], and UAE[25] and genotype 1 was more 
prominent in Turkey[26] and Russia[27].  
  Furthermore, because of differences in geographical 
distribution of HCV genotype even in the same country due 
to distribution of different at risk population, genotyping 
is an important tool not only for investigating the origin of 
the HCV outbreak but also for determining the response 
to interferon therapy, the progression of liver disease, and 
the outcome of HCV infection. Increasing in prevalence of 
genotype 3a in our study population have several messages 
such as HCV genotypes seems to be slightly changed, the 
potential implications of HCV genotyping in patient selection 
for appropriate HCV treatment as individuals infected by 
this genotype have more chance to respond to combination 
therapy. On the other hand, patients with HCV genotype 3a 
are more likely to response to routine anti viral therapy while 
infected patients with genotype 1 may need approximately 2 
times longer anti viral treatment. 
  Interestingly, approximately 11.9% of our participants 
infected with more than one distinct genotype indicated 
possibility of the new infection. Furthermore, the most 
frequent mixed genotypes were 1a and 3a. Infection with two 
or more distinct HCV genotypes was reported in some studies 
with higher prevalence rates in multiple exposure groups 
such as hemophiliacs, patients on chronic hemodialysis, and 
IDAs. Mixed viral infection is of great clinical importance 
as it may result in more severe disease, failure to antiviral 
treatment or relapse of infection after the completion of 
antiviral therapy course[28-30]. Although HCV genotype 
pattern of our participants are similar to western countries, 
infection of our subjects with two or more HCV genotypes is 
an exception. Therefore, it might be due to delay in applying 
anti-HCV screening of blood products in Iran, which started 
from 1996[31], in comparison to other countries, multiple 
exposures to HCV in our high potential risk groups and 
resultant reinfection of previously HCV-infected patients. 
  Intravenous drug addicts were more vulnerable to infected 
to genotype 1 and subtype 1a and 1b. These findings are 
in contrast to studies in Europe and North America shown 
a dominant 3a genotype in IDAs[32]. Our result is resemble 
to studies from Puerto Rico[33] and Brazil[34,35] showed 1a 
and 1b and the less turn 3a were more frequent in IDAs. 
Genotypes 1a and 3a are nominated as the IDAs-associated 
genotypes. It is noteworthy that the most (8.2%) mixed HCV 
genotypes detected in our participants were 1a and 1b 
which found in IDAs. Since IDAs become infected with HCV 
in the early phases of drug addiction and most become 
exposed repeatedly to the virus through needle-sharing, 
it is expected that infection with more than one genotype 
would be common[30,32,36]. It might be a public health threat 
because of  genotype 1b is reportedly associated with a 
more severe liver disease such as  chronic active hepatitis 
or cirrhosis, and with a poorer response to treatment with 
interferon than other types of HCV genomes[37]. Since the 
addiction age is decreasing in Iran and a lot of addicts 
are IDAs, it might change the subtype pattern of HCV in 
general population. On the other hand, it has demonstrated 
that some countries of Europe, genotype 1a and 3a are 
increasing, while 2a, 2c and 1b are decreasing, especially in 
young patients[18].
 In conclusion, this study is the first report on HCV genotypes 
among Iranian subjects with different exposure categories 
resided in Mazandaran, where genotype 3a was found to be 
the most frequent genotype in thalassemia, hemophilia and 
HD patients but not in IDAs. Intravenous drug addicts were 
more vulnerable to infect to subtypes 1a and 1b. Since the 
addiction age is decreasing in Iran and a lot of addicts are 
IDAs, it  might change the subtype pattern of HCV in general 
population. 
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